AU2022310182A1 - Bifunctional compounds for degrading btk with diminished imid activity - Google Patents

Bifunctional compounds for degrading btk with diminished imid activity Download PDF

Info

Publication number
AU2022310182A1
AU2022310182A1 AU2022310182A AU2022310182A AU2022310182A1 AU 2022310182 A1 AU2022310182 A1 AU 2022310182A1 AU 2022310182 A AU2022310182 A AU 2022310182A AU 2022310182 A AU2022310182 A AU 2022310182A AU 2022310182 A1 AU2022310182 A1 AU 2022310182A1
Authority
AU
Australia
Prior art keywords
alkyl
membered
compound
heterocycloalkyl
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022310182A
Other languages
English (en)
Inventor
Cristiana Guiducci
Mark NOVISKI
Janine Powers
Ryan ROUNTREE
Ying Siow TAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nurix Therapeutics Inc
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of AU2022310182A1 publication Critical patent/AU2022310182A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022310182A 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity Pending AU2022310182A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221905P 2021-07-14 2021-07-14
US63/221,905 2021-07-14
PCT/US2022/037029 WO2023287928A1 (en) 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity

Publications (1)

Publication Number Publication Date
AU2022310182A1 true AU2022310182A1 (en) 2024-02-01

Family

ID=82799901

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022310182A Pending AU2022310182A1 (en) 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity

Country Status (9)

Country Link
US (1) US20240336595A1 (https=)
EP (1) EP4370123A1 (https=)
JP (1) JP2024525797A (https=)
KR (1) KR20240035837A (https=)
CN (1) CN118019538A (https=)
AU (1) AU2022310182A1 (https=)
CA (1) CA3225367A1 (https=)
IL (1) IL309796A (https=)
WO (1) WO2023287928A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2024524480A (ja) * 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2025162210A1 (zh) * 2024-02-04 2025-08-07 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途
WO2026005533A1 (ko) * 2024-06-27 2026-01-02 한미약품 주식회사 신규한 이종이작용기 단백질 분해제 및 이의 용도
CN120590386A (zh) * 2025-05-30 2025-09-05 北京科莱博医药开发有限责任公司 一种喹喔啉类蛋白降解剂及其制备方法和应用
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
IL309796A (en) 2024-02-01
WO2023287928A1 (en) 2023-01-19
KR20240035837A (ko) 2024-03-18
EP4370123A1 (en) 2024-05-22
CN118019538A (zh) 2024-05-10
US20240336595A1 (en) 2024-10-10
CA3225367A1 (en) 2023-01-19
JP2024525797A (ja) 2024-07-12

Similar Documents

Publication Publication Date Title
EP4069237B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US20240336595A1 (en) Bifunctional compounds for degrading btk with diminished imid activity
US11866442B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12582722B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP4055019B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
KR20240039001A (ko) 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물
US20250002489A1 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2007284350A1 (en) Modulators of muscarinic receptors